CJ Bioscience Faces Staff Departures, Halts Cancer Drug Trials Amid Strategic Shift

CJ Bioscience is undergoing a major strategic overhaul, marked by a substantial exodus of research and development personnel and the discontinuation of its flagship cancer drug trials. The departure of roughly 20% of its R&D workforce has raised significant questions about the company's future direction and the viability of its innovative microbiome-based therapies. The decision to halt clinical trials for its immune-oncology drug, developed over seven years, signals a critical reassessment of its research pipeline. This move follows a period of intense focus on harnessing the power of the human microbiome for cancer treatment. The company's recent financial disclosure, reporting first-quarter consolidated revenue of approximately 800 million KRW, underscores the financial pressures that may be influencing these drastic changes. The industry is watching closely to see how CJ Bioscience will navigate these turbulent times and redefine its research and development strategy in the competitive biopharmaceutical landscape.